Renal Transplant Skin Cancer Post-Immunotherapy

Patients undergoing renal transplantation typically require immunosuppressive therapy, often referred to as immunotherapy, to prevent organ rejection. This therapy suppresses the immune system, increasing the risk of various complications, including malignancies.

Among the various risks associated with long-term immunosuppression post-renal transplant, skin cancers become notably more common. The question asks for the most commonly seen skin cancer type.

Common Post-Transplant Skin Cancers

• Immunosuppression impairs the immune system's ability to detect and eliminate abnormal or cancerous cells, including those originating in the skin.
• Factors like viral infections (e.g., Human Papillomavirus - HPV) and chronic sun exposure (UV radiation) are more likely to lead to skin cancer development in this vulnerable population.
• While specific skin cancers like Kaposi's sarcoma or Mycosis Fungoides can occur, the overall category of Skin tumors, particularly non-melanoma skin cancers (like basal cell carcinoma and squamous cell carcinoma), represents the most frequent neoplastic complication affecting the skin.

Therefore, the general classification of Skin tumors is the most accurate answer for the most commonly seen skin cancer in renal transplant patients following immunotherapy.